Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

6,972 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma: results of a randomized trial with epirubicin comparing short-term versus long-term maintenance treatment.
Nomata K, Noguchi M, Kanetake H, Tsuda N, Hayashi M, Yamashita S, Sakuragi T, Kusaba Y, Shindo K; Nagasaki Clinical Research Group for Bladder Cancer. Nomata K, et al. Among authors: hayashi m. Cancer Chemother Pharmacol. 2002 Oct;50(4):266-70. doi: 10.1007/s00280-002-0487-6. Epub 2002 Aug 24. Cancer Chemother Pharmacol. 2002. PMID: 12357299 Clinical Trial.
[Efficacy of naftopidil in patients with overactive bladder associated with benign prostatic hyperplasia: prospective randomized controlled study to compare differences in efficacy between morning and evening medication].
Sakai H, Igawa T, Onita T, Furukawa M, Hakariya T, Hayashi M, Matsuya F, Shida Y, Nishimura N, Yogi Y, Tsurusaki T, Takehara K, Nomata K, Shiraishi K, Shono T, Aoki D, Kanetake H. Sakai H, et al. Among authors: hayashi m. Hinyokika Kiyo. 2011 Jan;57(1):7-13. Hinyokika Kiyo. 2011. PMID: 21304253 Free article. Clinical Trial. Japanese.
Hot flashes during androgen deprivation therapy with luteinizing hormone-releasing hormone agonist combined with steroidal or nonsteroidal antiandrogen for prostate cancer.
Sakai H, Igawa T, Tsurusaki T, Yura M, Kusaba Y, Hayashi M, Iwasaki S, Hakariya H, Hara T, Kanetake H. Sakai H, et al. Among authors: hayashi m. Urology. 2009 Mar;73(3):635-40. doi: 10.1016/j.urology.2008.09.013. Epub 2008 Nov 26. Urology. 2009. PMID: 19038426 Free article. Clinical Trial.
Evaluation of quality of life in patients with previously untreated advanced prostate cancer receiving maximum androgen blockade therapy or LHRHa monotherapy: a multicenter, randomized, double-blind, comparative study.
Arai Y, Akaza H, Deguchi T, Fujisawa M, Hayashi M, Hirao Y, Kanetake H, Naito S, Namiki M, Tachibana M, Usami M, Ohashi Y. Arai Y, et al. Among authors: hayashi m. J Cancer Res Clin Oncol. 2008 Dec;134(12):1385-96. doi: 10.1007/s00432-008-0409-z. Epub 2008 May 20. J Cancer Res Clin Oncol. 2008. PMID: 18491137 Clinical Trial.
The Complex Roles of Redox and Antioxidant Biology in Cancer.
Hayashi M, Okazaki K, Papgiannakopoulos T, Motohashi H. Hayashi M, et al. Cold Spring Harb Perspect Med. 2024 May 21:a041546. doi: 10.1101/cshperspect.a041546. Online ahead of print. Cold Spring Harb Perspect Med. 2024. PMID: 38772703
Nucleobindin 2 inhibits senescence in gastric carcinoma.
Ishibashi Y, Itoh T, Oguri Y, Hashimura M, Yokoi A, Matsumoto T, Harada Y, Fukagawa N, Hayashi M, Ono M, Kusano C, Saegusa M. Ishibashi Y, et al. Among authors: hayashi m. Sci Rep. 2024 May 17;14(1):11261. doi: 10.1038/s41598-024-61111-5. Sci Rep. 2024. PMID: 38760405 Free PMC article.
6,972 results